Glycotest is developing blood tests for the large populations at risk of developing liver cancers and fibrosis-cirrhosis.
Glycotest has raised $3.2M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in July 2026.
Glycotest's investors include Fosun Pharma.
Glycotest is headquartered in New York, United States.
Glycotest is developing blood tests for the large populations at risk of developing liver cancers and fibrosis-cirrhosis.
Glycotest is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Glycotest — Funding & Investors." VCBacked, July 1, 2026, https://www.vcbacked.co/company/glycotest. Accessed August 14, 2026.
VCBacked. (2026). Glycotest — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/glycotest
{{cite web |title=Glycotest — Funding & Investors |url=https://www.vcbacked.co/company/glycotest |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated